Inato

Inato is a technology company that has built a clinical trial platform intended to unite pharmaceutical sponsors, research sites and patients within a single AI-powered marketplace. The system matches community-based research sites with suitable clinical trials, with the stated aim of widening patient access to medical innovations irrespective of geography. The marketplace launched in June 2020 and now connects more than 6,000 research sites across over 50 countries.

The company's technical work spans artificial intelligence, machine learning and marketplace engineering applied to clinical research. Its AI-powered planning and enrollment tools support early trial planning, site selection and patient pre-screening, designed to make trials more accessible and inclusive while reducing site burden and shortening enrollment timelines. Site selection algorithms and pre-screening models are central to how the platform pairs sponsors with research partners.

Inato works with pharmaceutical sponsors including Sanofi, Pfizer, Amgen, Lilly, AstraZeneca and Kailera. The company operates from headquarters in Neuilly-sur-Seine, France, with a presence in the United States and a network spanning more than 50 countries. Its stated focus is on making clinical trials more accessible and inclusive, on diversity and patient access regardless of where patients live, and on improving efficiency for research sites.

Its work sits at the intersection of pharmaceuticals, clinical research, healthcare, life sciences and biotechnology. Further information is available at https://inato.com/.